NCT06163729View on ClinicalTrials.gov

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 25, 2022

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2028

Conditions
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Interventions
DRUG

Camrelizumab+Oxaliplatin+Paclitaxel (Albumin Bound) +radiotherapy

Durg：Camrelizumab: 200mg, iv, d1, q3w Durg ：Oxaliplatin, 100mg/m2 , iv, d1, q3w Durg ：Paclitaxel(Albumin Bound), 125mg/m2, iv, d1, d8, q3w； Durg ：Radiotherapy, PGTV：45.1Gy/2.05Gy/ 22f； PTV：40.04Gy/1.82Gy/ 22f；Five days a week for more than four weeks

Trial Locations (1)

100020

RECRUITING

Shugeng Gao, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER